🧬 biology

EGFR as a Potential Molecular Target of Cleistanthin A and Diphyllin Derivatives: An Integrated Computational and Biophysical Study

This study integrates computational modeling and biophysical experiments to identify the epidermal growth factor receptor (EGFR) as a primary molecular target of the anticancer lignan Cleistanthin A and its derivatives, demonstrating their strong binding affinity and stability as potential scaffolds for developing novel EGFR inhibitors.

Original authors: Bunnatut Panasawatwong, Duangporn Lohawittayanan, Napason Chabang, Sitthivut Charoensutthivarakul, Sakonwan Kuhaudomlarp, Bamroong Munyoo, Patoomratana Tuchinda, Noppawan Phumala Morales, Supachoke Ma

Published 2026-08-12

📖 6 min read🧠 Deep dive

CC BY 4.0

Original authors: Bunnatut Panasawatwong, Duangporn Lohawittayanan, Napason Chabang, Sitthivut Charoensutthivarakul, Sakonwan Kuhaudomlarp, Bamroong Munyoo, Patoomratana Tuchinda, Noppawan Phumala Morales, Supachoke Mangmool, Somrudee Reabroi, Pimtip Sanvarinda, Bodee Nutho

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

Imagine the human body as a bustling, high-tech city where trillions of cells are the citizens. Sometimes, the traffic lights in this city break, causing cars (cells) to speed uncontrollably, leading to a chaotic pile-up known as cancer. To fix this, scientists act like master mechanics, trying to find the specific broken switch that keeps the traffic lights stuck on "go." One of the most famous switches in this city is a protein called EGFR (Epidermal Growth Factor Receptor). Think of EGFR as a super-sensitive doorbell on the surface of a cell; when it rings, it tells the cell to grow and divide. In some cancers, this doorbell gets stuck in the "ringing" position, screaming for the cell to multiply even when it shouldn't.

For decades, scientists have tried to build a "silencer" for this doorbell—a drug that fits perfectly into the switch to stop the noise. However, building these silencers is like trying to find a needle in a haystack while wearing blindfolded gloves. It takes years, costs a fortune, and most attempts fail. This is where a new kind of detective work comes in: Computer-Aided Drug Design (CADD). Instead of mixing chemicals in a lab first, scientists use powerful supercomputers to simulate millions of potential drug molecules, testing how well they might fit into the broken switch on a digital screen. If the computer says, "Hey, this shape looks like it could jam the doorbell," then—and only then—do scientists try to build it in real life. This approach saves time, money, and helps us understand the microscopic mechanics of life without needing to test everything on animals first.

The Digital Hunt for a Cancer Silencer

In this study, a team of researchers from Mahidol University and Chiang Mai University in Thailand decided to investigate a group of natural compounds found in plants, specifically a molecule called Cleistanthin A (CTA) and its chemical cousins, the diphyllin derivatives. These compounds are like nature's own toolbox of complex shapes, known to be toxic to cancer cells, but scientists weren't entirely sure exactly which part of the cell's machinery they were jamming. Was it the doorbell (EGFR)? Was it something else entirely?

The researchers set up a multi-stage digital investigation. First, they used a computer program called SwissTargetPrediction to guess the target. It was like asking a crystal ball, "If you were a lock, what key would fit?" The crystal ball pointed a finger at protein kinases, a family of enzymes that includes the EGFR doorbell. To be sure, the team then ran a molecular docking simulation. Imagine this as a high-speed video game where they threw thousands of virtual versions of CTA and its derivatives into a digital model of the EGFR protein to see if they could wedge themselves into the ATP-binding pocket (the energy slot where the protein gets its power).

The results were surprisingly promising. In the computer simulation, CTA and its derivatives didn't just fit; they seemed to hug the EGFR protein even tighter than erlotinib, a famous, FDA-approved cancer drug used as the gold standard for comparison. One specific derivative, Compound 2, scored the highest, followed closely by Compound 1. The computer suggested that these plant-based molecules were excellent candidates for jamming the EGFR switch.

The Virtual Dance and the Energy Math

But a static picture isn't enough. In the real world, proteins wiggle and dance. So, the researchers ran Molecular Dynamics (MD) simulations, which are like watching a 200-second movie of the drug and the protein dancing together in a virtual water tank. They watched to see if the drug would slip off or if the protein would fall apart. The movie showed that the complexes were stable; the drugs held on tight, and the protein didn't unravel.

To understand why they held on so well, the team used a mathematical method called MM/PB(GB)SA to calculate the energy of the bond. They discovered that the main force holding the drugs to the EGFR protein wasn't electrical attraction, but van der Waals interactions. Think of this like Velcro or the way a magnet sticks to a fridge due to surface contact. The study found that the "non-polar" (oily, water-hating) parts of the drug molecules were the real heroes, creating a snug fit in the oily pocket of the EGFR protein. Interestingly, adding a specific chemical group called a benzoyl ester (which is like adding a fuzzy, sticky patch to the drug) made the bond even stronger, especially in derivatives like MUC-853 and MUC-858.

The Real-World Test: The Surface Plasmon Resonance

Computers are great, but they can't replace reality. To prove their digital findings, the team moved to the lab to perform a test called Surface Plasmon Resonance (SPR). Imagine a sensor that can feel a molecule sticking to a surface, like a very sensitive scale that detects weight without touching it. They coated a sensor chip with the EGFR protein and then flowed the drug solutions over it.

The results confirmed the computer's hunch. Several compounds, including CTA, MUC-853, MUC-858, and Compound 1, actually stuck to the EGFR protein in a concentration-dependent way (meaning the more drug they added, the stronger the stickiness). However, not all of them were perfect. While the computer predicted strong binding for everyone, the real-world sensor showed that Compound 1 and MUC-858 were the clear winners, with dissociation constants (KD) of 6.4 µM and 9.5 µM, respectively. These numbers represent how tightly they hold on; lower is better.

What This Means (and What It Doesn't)

The study concludes that the arylnaphthalide lignan scaffold (the core structure of CTA and its derivatives) is a very promising shape for designing new drugs that target EGFR. The research suggests that by tweaking the chemistry—specifically by adding those "fuzzy" halogenated groups—they can make the drugs stick even tighter to the cancer-causing protein.

However, it is important to keep the excitement in check. The paper explicitly states that these findings are based on simulations and biophysical binding tests. They have shown that the drugs can bind to the protein in a test tube and on a computer screen, but they have not yet proven that these drugs will kill cancer cells in a living body or cure a patient. The researchers note that further work is needed to test these compounds on mutant forms of EGFR (the trickier versions found in patients) and to see if they work in actual cells and animals.

In short, this paper is a successful "proof of concept." It suggests that nature has already built a key that fits the EGFR lock, and with a little bit of chemical engineering, we might be able to turn that key into a powerful new tool for fighting cancer. But the journey from a computer screen to a medicine cabinet is still long, and this study is just a very encouraging first step.

Technical Summary: EGFR as a Potential Molecular Target of Cleistanthin A and Diphyllin Derivatives

Problem Statement
Traditional drug discovery is characterized by high costs, long timelines, and a high failure rate, with approximately 90% of candidates failing during clinical development. While computer-aided drug design (CADD) offers a paradigm shift toward rapid, cost-effective target identification and lead optimization, the specific molecular targets of many bioactive natural products remain unclear. Cleistanthin A (CTA), an arylnaphthalide lignan glycoside derived from Cleistanthus collinus and Phyllanthus taxodiifolius, is known for its cytotoxicity against various cancer cell lines. However, its mechanism of action is multifaceted, involving DNA synthesis inhibition, V-ATPase inhibition, and apoptosis induction, leaving its potential as a specific kinase inhibitor unexplored. This study addresses the need to identify a precise molecular target for CTA and its derivatives to facilitate the rational design of next-generation anticancer agents, particularly for non-small cell lung cancer (NSCLC), where Epidermal Growth Factor Receptor (EGFR) dysregulation is prevalent.

Methodology
The study employed an integrated workflow combining in silico computational methods with experimental biophysical validation:

Target Prediction: The SwissTargetPrediction server was utilized to predict potential protein targets for CTA based on its chemical structure, identifying protein kinases as a primary target class.
Molecular Docking: CTA and a series of synthesized derivatives (including halobenzoate glycosides MUC-853/MUC-858 and O-substituted diphyllin analogs 1–5) were docked against the kinase domains of oncogenic proteins frequently mutated in NSCLC (EGFR, ALK, BRAF, c-MET, ROS1, RET). Erlotinib served as the reference inhibitor.
Molecular Dynamics (MD) Simulations: To assess complex stability beyond rigid docking, 200 ns MD simulations were performed for top-ranked compounds in complex with wild-type EGFR (WT-EGFR). Stability was evaluated via Root-Mean-Square Deviation (RMSD), Radius of Gyration (Rg), and hydrogen bond occupancy.
Binding Free Energy Calculations: The Molecular Mechanics Poisson-Boltzmann (Generalized Born) Surface Area (MM/PB(GB)SA) method was applied to the final 50 ns of trajectories to calculate total binding free energies ( $\Delta G_{total}$ ) and decompose energy contributions (van der Waals, electrostatic, solvation). Per-residue free energy decomposition identified specific "hot-spot" residues.
Synthesis: New derivatives were synthesized via etherification or esterification of the C-4 hydroxyl group of diphyllin or modification of the glycosidic moiety of CTA. Structures were confirmed by NMR.
Surface Plasmon Resonance (SPR): Direct physical binding to the EGFR kinase domain was validated using SPR on a Biacore X100 instrument. Dissociation constants ( $K_D$ ) were determined for compounds showing dose-dependent responses.

Key Results

Target Identification and Docking: Target prediction highlighted protein kinases. Docking against WT-EGFR revealed that all tested compounds exhibited superior predicted binding affinities compared to erlotinib. Compound 2 showed the highest docking score (−11.22 kcal/mol), followed by Compound 1 (−11.09 kcal/mol).
Structural Stability: MD simulations confirmed that protein-ligand complexes remained stable, with RMSD values stabilizing between 2.6 and 4.3 Å after initial fluctuations. The complexes maintained compact conformations (Rg 19.20–20.99 Å) and sustained 2–7 intermolecular hydrogen bonds throughout the simulation.
Thermodynamic Drivers: MM/GBSA and MM/PBSA analyses indicated that van der Waals interactions ( $\Delta E_{vdW}$ ) were the primary driving force for binding, contributing 2–4 times more than electrostatic interactions. The halobenzoate glycoside derivatives (MUC-853 and MUC-858) displayed the most favorable total binding free energies (−46.71 and −47.06 kcal/mol via MM/GBSA, respectively), outperforming both CTA and erlotinib.
Interaction Hotspots: Per-residue decomposition showed that CTA and its derivatives interacted with key ATP-binding pocket residues (Leu718, Val726, Leu792, Met793) similar to erlotinib. MUC-853 and MUC-858 demonstrated enhanced energy contributions at Leu718 and Val726, attributed to additional halogen bonds and hydrophobic interactions.
SPR Validation: SPR confirmed concentration-dependent binding for CTA, MUC-853, MUC-858, Compound 1, and Compound 2. Compound 1 and MUC-858 yielded the most promising dissociation constants ( $K_D$ ) of 6.4 µM and 9.5 µM, respectively. Compound 2 and CTA showed binding responses but could not be fitted to a standard binding model under the tested conditions.

Significance and Claims
The authors claim that this study successfully establishes an integrated CADD-driven workflow to identify EGFR as a potential molecular target for the arylnaphthalide lignan scaffold. The research provides atomic-level insights into the protein-ligand interactions, demonstrating that the incorporation of lipophilic halogenated moieties (specifically halobenzoate groups) enhances non-polar binding energy within the EGFR ATP-binding pocket.

The paper posits that CTA and its derivatives, particularly MUC-858 and Compound 1, represent a promising scaffold for the rational design of next-generation EGFR inhibitors. The findings suggest that optimizing these derivatives to improve potency and selectivity, particularly against clinically relevant EGFR mutants, is a viable pathway for drug discovery. The authors explicitly state that the study is limited to computational and biophysical analyses, and further validation using cell-based and in vivo models is required to confirm the biological relevance of these findings.

More like this